What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Pathology
Internal medicine, Pathology, Glomerulonephritis, Gastroenterology and Immunology are his primary areas of study.
Many of his studies involve connections with topics such as Surgery and Internal medicine.
His Pathology research incorporates themes from Monoclonal gammopathy of undetermined significance, Nephropathy and Renal pathology.
His Glomerulonephritis study incorporates themes from Alternative complement pathway and Nephrotic syndrome.
His Gastroenterology research is multidisciplinary, relying on both Remission induction and Treatment failure.
He interconnects Regimen, Cyclophosphamide, Vasculitis, Anti-neutrophil cytoplasmic antibody and Prednisone in the investigation of issues within Rituximab.
His most cited work include:
- Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis (1616 citations)
- Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis (781 citations)
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study† (763 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Pathology, Immunology, Gastroenterology and Proteinuria.
His study in Internal medicine concentrates on Rituximab, Nephrology, Renal function, Kidney disease and Kidney.
As a member of one scientific family, Fernando C. Fervenza mostly works in the field of Rituximab, focusing on Vasculitis and, on occasion, Azathioprine.
Fernando C. Fervenza usually deals with Pathology and limits it to topics linked to Glomerulonephritis and Alternative complement pathway.
His biological study spans a wide range of topics, including Immunosuppression, Adverse effect, Surgery and Kidney transplantation.
His study explores the link between Membranous nephropathy and topics such as Nephrotic syndrome that cross with problems in Focal segmental glomerulosclerosis.
He most often published in these fields:
- Internal medicine (47.70%)
- Pathology (35.92%)
- Immunology (23.85%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (47.70%)
- Membranous nephropathy (15.52%)
- Gastroenterology (22.99%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Membranous nephropathy, Gastroenterology, Biopsy and Pathology.
His study in Renal function, Rituximab, Proteinuria, Vasculitis and Kidney disease is carried out as part of his Internal medicine studies.
He has researched Membranous nephropathy in several fields, including Refractory, Obinutuzumab, Autoimmune disease, Antibody and Properdin.
His research integrates issues of Fibrillary Glomerulonephritis and Glomerulonephritis in his study of Gastroenterology.
His Biopsy research includes themes of Focal segmental glomerulosclerosis, Kidney and Lesion.
His Pathology research integrates issues from Glomerular basement membrane, Eculizumab, Antigen and Glomerulopathy.
Between 2018 and 2021, his most popular works were:
- The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. (119 citations)
- Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy (94 citations)
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials (81 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Surgery
Fernando C. Fervenza mainly focuses on Internal medicine, Membranous nephropathy, Gastroenterology, Biopsy and Renal function.
His Internal medicine study integrates concerns from other disciplines, such as Nephropathy and Allele.
The various areas that Fernando C. Fervenza examines in his Gastroenterology study include Anti-neutrophil cytoplasmic antibody, Retrospective cohort study and Rituximab.
Biopsy is a subfield of Pathology that Fernando C. Fervenza tackles.
He combines subjects such as Antibody and Glomerulopathy with his study of Pathology.
The Renal function study combines topics in areas such as Dialysis and Kidney.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
